[1]NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Non-Small Cell Lung Cancer, Version 11.2024, October 15, 2024. 整理:王福栋;
➤参考文献 40 新增:Solomon BJ, Drilon A, Lin JJ, et al. Repotrectinib in patients with NTRK fusion-positive advanced solid tumors, including non-small cell lung cancer: update from the phase 1/2 TRIDENT-1 trial. Ann Oncol, 2023; 34: S787-S788. 八、2024 Version 8 版本在 2024 Ve...
[1]NCCN Guidelines Version 4.2024 Non-Small Cell Lung Cancer. [2]2022.《NCCN肿瘤学临床实践指南:非小细胞肺癌》 [3] FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer | FDA https://www.fda.gov/ne...
[2]Oshima,Y.,Tanimoto,T.,Yuji,K.,&Tojo,A.(2018).EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer.JAMA Oncology,4(8),1112–1115.https://doi.org/10.1001/jamaoncol.2017.4526 [3]Shih J-Y,et al.Amivantamab plus chemotherapy vs chemoth...
9月5日,NCCN发布了2024.V1版小细胞肺癌(SCLC)诊疗指南。与2023.V3版本比较,最新版更新了分子检测的适应证范围、广泛修订后续全身治疗方案、新增非小细胞肺癌(NSCLC)转化性SCLC治疗原则,以及更新和补充了多处参考依据等内容。医脉通编辑整理翻译,与读者共享相较于2023.V3版,新版指南的更新要点和相关临床证据。
EMPOWER-Lung 3研究截图 6、鳞癌免疫治疗推荐:西米普利单抗+紫杉醇+(卡铂/顺铂)(1类证据):由“其他推荐方案”→“优选方案”。 适用人群: ①PD-L1≥50%的鳞状细胞癌的一线治疗(PS 0-2)。 指南推荐截图 ②PD-L1≥1%-49%的鳞状细胞...
[2] Solomon BJ,Drilon A,Lin JJ,et al.Repotrectinib in patients with NTRK fusion-positive advanced solid tumors,including non-small cell lung cancer:Update from the phase 1/2 TRIDENT-1 trial[abstract].Ann Oncol 2023;34:Abstract 1372P. ...
[1]NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Non-Small Cell Lung Cancer, Version 7.2024, June 26, 2024. [2]Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC | New England Journal of Medicine. https://www.nejm.org/doi/10.1056/NEJMoa2402614?url_ver=...
SCL-F 1 of 7新增:Zhang C, Zhao G, Wu H, et al. Application of postoperative adjuvant radiotherapy in limited stage small cell lung cancer: A systematic review and meta-analysis. Radiother Oncol 2024;193:110123. SCL-F 4 of 7新增:Gondi V, Pugh S, Mehta MP, et al. Primary Endpoint...
小细胞肺癌NCCN指南2024.v2版更新!扩大初始评估分子检测的推荐人群 小细胞肺癌(SCLC, small cell lung cancer)约占所有肺癌患者的1/4,据统计全球每年有近25万的SCLC新发病例。由于其高侵袭性及易转移的特点,近2/3的患者在诊断初期就已为广泛期小细胞肺癌(ES-SCLC),从而失去了手术机会。化疗是ES-SCLC的标准治疗...